Popular terms

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Vaccine patents



      

This page is updated frequently with new Vaccine-related patent applications.




Date/App# patent app List of recent Vaccine-related patents
04/07/16
20160097768 
 Polyvalent chimeric ospc vaccinogen and diagnostic antigen patent thumbnailPolyvalent chimeric ospc vaccinogen and diagnostic antigen
Chimeric polyvalent recombinant proteins for use as vaccines and diagnostics for lyme disease (e.g. In canines and humans) are provided.
Virginia Commonwealth University


04/07/16
20160095918 
 Rapid, efficient purification of hsv-specific t-lymphocytes and hsv antigens identified via same patent thumbnailRapid, efficient purification of hsv-specific t-lymphocytes and hsv antigens identified via same
A method of identifying an immunologically active antigen of a virus that attacks skin, as well as a method of enriching a population of lymphocytes for t lymphocytes that are specific to a virus that attacks skin. Also provided are hsv antigens and epitopes that are useful for the prevention and treatment of hsv infection that have been identified via the methods of the invention.
University Of Washington


04/07/16
20160095917 
 Dps fusion proteins for use in vaccines and diagnostics patent thumbnailDps fusion proteins for use in vaccines and diagnostics
Novel nanoparticle fusion proteins comprising proteins or peptides fused to dps (dna binding protein from starved cells) proteins are provided which bring forth distinct advantages for development of new and improved vaccines, diagnostic tests, and other biomedical products.. .
Kj Biosciences Llc


04/07/16
20160095913 
 Controlled release vaccines and methods of treating brucella diseases and disorders patent thumbnailControlled release vaccines and methods of treating brucella diseases and disorders
Methods and compositions for the treatment of brucella induced diseases and disorders are disclosed herein. In preferred embodiments, the invention relates to vaccines.
The Texas A&m University System


03/31/16
20160089432 
 Methods and compositions for inducing protective immunity against human immunodeficiency virus infection patent thumbnailMethods and compositions for inducing protective immunity against human immunodeficiency virus infection
Compositions, vaccines and methods for inducing protective immunity against human immunodeficiency virus (hiv) infection are described. Heterologous vaccine combinations of one or more viral expression vectors and an isolated antigenic polypeptide induced strong protective immunity against infections by one or multiple clades of hiv..
Crucell Holland B.v.


03/31/16
20160089431 
 Nanodisk-associated immunogen super polyvalent vaccines patent thumbnailNanodisk-associated immunogen super polyvalent vaccines
Disclosed are compositions of matter consisting of collections of nanodisks associated with polypeptide immunogens. Each said collection contains multiple epitopes of at least one immunogen.
Shiva Science & Technology Group Llc


03/31/16
20160089430 
 Compositions containing ambient-temperature stable, inactivated but therapeutically active biopharmaceuticals & methods for formulation thereof patent thumbnailCompositions containing ambient-temperature stable, inactivated but therapeutically active biopharmaceuticals & methods for formulation thereof
The disclosure concerns compositions containing inactivated but therapeutically active biopharmaceuticals, and methods for formulation thereof. Biopharmaceuticals are encapsulated and immobilized in dry amorphous carbohydrate-glass and irradiated for inactivation while in the dry state.
Universal Stabilization Technologies, Inc.


03/31/16
20160089427 
 Genetically modified yersinia as vaccines against yersinia species patent thumbnailGenetically modified yersinia as vaccines against yersinia species
Recombinant attenuated y. Pseudotuberculosis mutants have been created that show efficacy as oral vaccines against plague caused by y.
Arizona Board Of Regents On Behalf Of Arizona State University


03/31/16
20160089397 
 Correlates of efficacy relating to tumor vaccines patent thumbnailCorrelates of efficacy relating to tumor vaccines
The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through a combination of ex vivo gene therapy protocols and cell enchment, tumor cells are engineered to express an α (1,3)galactosyl epitope and optionally the tumor associated antigens mesothelin and carcinoembryonic antigen.
Newlink Genetics Corporation


03/24/16
20160083757 
 Enzymatic process for the production of mannosylerythritol lipids from lignocellulosic materials patent thumbnailEnzymatic process for the production of mannosylerythritol lipids from lignocellulosic materials
The present invention relates to processes for the production of microbial glycolipids, mannosylerythritol lipids (mel), from lignocellulosic carbon source. These processes are characterized in that the use of lignocellulosic materials for the production of a microbial glycolipids, mel, comprising a fermentation preferably using fungi of the genus pseudozyma or other microorganisms such as genetically modified fungi or bacteria.
LaboratÓrio Nacional De Energia E Geologia


03/24/16
20160083439 

Novel vaccines against apicomplexan pathogens


The technology provided herein generally relates to novel fusion proteins suitable as human and/or animal vaccines against parasites or pathogens of the phylum apicomplexa. In particular, the present disclosure relates to novel fusion proteins as a basis for vaccines against plasmodium parasites, including p.
Fraunhofer-gesellschaft Zur FÖrderung Der Angew Andten Forschung E.v.


03/24/16
20160082099 

Attenuated african swine fever virus strain induces protection against challenge with homologous virulent parental virus georgia 2007 isolate


African swine fever virus (asfv) is the etiological agent of a contagious and often lethal viral disease of domestic pigs that has significant economic consequences for swine breeding. Control of asf has been hampered by the unavailability of vaccines.
The University Of Connecticut


03/24/16
20160082097 

Neisserial vaccine compositions comprising a combination of antigens


The present invention relates to immunogenic compositions and vaccines for the treatment and prevention of neisserial disease. Immunogenic compositions of the invention contain combinations of antigens selected from at least two different classes of antigens including adhesins, autotransporter proteins, toxins, iron acquisitions proteins and membrane-associated protein (preferably integral outer membrane protein)s.
Glaxosmithkline Biologicals S.a.


03/24/16
20160082093 

Mucinous glycoprotein (muc-1) vaccine


The present invention provides a method for treating an individual who is afflicted with a cancer, such as non-small cell lung cancer or prostate cancer, by administering to that individual a muc-1 based formulation. The formulation may be a muc-1 based liposomal vaccine formulation..
Oncothyreon Inc.


03/17/16
20160076109 

Allogeneic autophagosome-enriched composition for the treatment of disease


A method is presented for screening cells that produce allogeneic autophagosome enriched compositions able to induce expression of a selective marker on a subpopulation of peripheral blood mononuclear cells, the method comprising contacting a cell with a proteasome inhibitor, contacting the cell with a lysosome inhibitor, harvesting the resulting autophagosomes, determining a molecular signature of the harvested autophagosomes, and selecting cells that divert one or more toll-like receptor agonist and/or one or more molecular chaperones to the harvested autophagosomes. By screening for cells that divert one or more toll-like receptor agonist and/or one or more molecular chaperones to the harvested autophagosomes, enriched populations of autophagosomes may be generated which may illicit a specific immune response against numerous cancer types.
Ubivac, Llc


03/17/16
20160076006 

Thermosensitive mutants of influenza viruses


The invention relates to thermosensitive mutants of influenza viruses, containing at least one mutation localised in a flexible region of a protein of said virus, such as especially the region of the sub-unit pa of the viral polymerase corresponding to the region 197-225 of the sub-unit pa of influenza a. These viruses can be especially used for preparing attenuated living vaccines..
Institut National De La Recherche Agronomique


03/17/16
20160074504 

Nanoemulsion influenza vaccine


The present invention relates to methods for inducing an immune response to influenza in a subject comprising administering a nanoemulsion vaccine composition comprising an influenza immunogen or protein.. .
Nanobio Corporation


03/17/16
20160074502 

Recombinant subunit dengue virus vaccine


The present invention provides dengue virus vaccines and immunogenic compositions for administration to human subjects. The vaccine compositions of the present invention comprise recombinantly produced monomeric and/or dimeric forms of truncated dengue virus envelope glycoprotein that, when formulated together with an adjuvant and a pharmaceutically acceptable carrier, induce balanced tetravalent immune responses.
Merck Sharp & Dohme Corp.


03/17/16
20160074500 

Infectious dna vaccines against chikungunya virus


Described herein are i-dna™ vectors and vaccines and methods for using the same. The i-dna™ generates live attenuated vaccines in eukaryotic cells in vitro or in vivo for pathogenic rna viruses, particularly chikungunya virus (chikv).
Medigen, Inc.


03/17/16
20160074497 

Staphylococcus live cell vaccines


Staphylococcus aureus protein a variants, defective in immunoglobulin binding, elicit protective immunity against staphylococcal disease. The present invention includes methods for preventing or ameliorating staphylococcal infections, particularly hospital acquired nosocomial infections.
The University Of Chicago


03/17/16
20160074492 

Oral vaccine for borrelia


The present invention relates to vaccines for control of borrelia infections in animal and human populations. In particular, the present invention provides compositions and methods comprising recombinant bacteria engineered to express one or more borrelia burgdorferi antigens for use as lyme disease vaccines.
Biopeptides, Corporation


03/10/16
20160068581 

Peptide vaccine for prevention and immunotherapy of dementia of the alzheimer's type


The present disclosure is directed to individual aβ peptide immunogen constructs, peptide compositions comprising these aβ peptide immunogen constructs and mixtures thereof, pharmaceutical compositions including vaccine formulations comprising these aβ peptide immunogen constructs, with the individual aβ peptide immunogen constructs having the n-terminus of the aβ peptide as the b cell (b) epitopes linked through spacer residue(s) to heterologous t helper cell (th) epitopes derived from pathogen proteins that act together to stimulate the generation of highly specific antibodies directed against the n-terminus of the aβ peptide offering protective immune responses to patients at risk for, or with, alzheimer's disease.. .
United Biomedical, Inc.


03/10/16
20160067334 

Vaccines with biomolecular adjuvants


Disclosed herein is a vaccine comprising an antigen and one or more bimolecular adjuvant. Also disclosed herein are methods for increasing an immune response in a subject.

03/10/16
20160067333 

Generating peptoid vaccines


The present invention provides for methods of identifying peptoid mimetics that will mimic b cell epitopes when delivered as vaccine compositions. One aspects of the invention is the use of monoclonal antibody that is broadly protective to select the mimetics, thereby identifying an epitope from a pathogen or other disease-causing agent that will be common among most or all variants of that pathogen or agent..
The Board Of Regents Of The University Of Texas System


03/10/16
20160067332 

E1e2 hcv vaccines and methods of use


The present disclosure provides immunogenic compositions comprising hcv e1, e2, or e1/e2 polypeptides from two or more different hcv genotypes. The present disclosure provides immunogenic compositions comprising hcv e2 or e1/e2 polypeptides from two or more different hcv genotypes.
The Governors Of The University Of Alberta


03/10/16
20160067331 

Viral proteins as immunomodulatory agents and vaccine components


The invention provides compositions and methods involving viral envelope polypeptides and peptides for use in modulating immune responses, including inhibition inflammation related to pathogenic t-cell activation. In addition, modification of the viral sequences responsible for modulating immune response provides for improved vaccine formulations..
The University Of Iowa Reseach Foundation


03/10/16
20160067330 

Herpes virus vaccines and treatments


Provided herein are vaccine compositions and methods of their use in treating or preventing herpes diseases.. .
The Regents Of The University Of California


03/10/16
20160067328 

Recombinant neuraminidase and uses thereof


A recombinant neuraminidase based on amino acid sequence (seq id no: 1) of wild-type ph1n1-na (a/texas/05/2009) influenza virus is provided. The recombinant neuraminidase of the present invention has an ectodomain with an amino acid sequence essentially identical to seq id no: 1 and replaced at specific positions 149, 344, 365 and 366 residue(s) with corresponding amino acids of other influenza viruses.
National Tsing Hua Univerisity


03/10/16
20160067327 

Omv vaccines


The invention is in the field of outer membrane vesicles (omv) and their uses. More particularly the present invention provides omv obtained from a bacterium being an ompa mutant and/or a mutant in one or more components of the tolpal complex and presenting a heterologous antigen on its surface.
Novartis Ag


03/10/16
20160067324 

Novel vaccine formulation for ocular immunization


The present invention relates generally to the field of ocular therapeutics and the development thereof for use in humans and animals including mammals and birds. More particularly, it relates to subunit vaccines that are effective against pathogens causing infections thereof for use in humans and animals including mammals and birds.
Medizinische UniversitÄt Wien


03/10/16
20160067321 

Method for treating pancreatic cancer with toxoplasma gondii vaccine


Attenuated toxoplasma gondii mutants and methods using the same as vaccines in the prevention or treatment pancreatic cancer are provided.. .
Trustees Of Dartmouth College


03/03/16
20160060325 

Monoclonal antibodies capable of reacting with a plurality of influenza virus a subtypes


Monoclonal antibodies directed against the influenza a virus are described, which have the advantageous and unpredicted property of being able to bind a plurality of subtypes of the influenza a virus. One preferred embodiment is the antibody designated as fab28, which displays a neutralizing activity against a plurality of subtypes of the influenza a virus.
Pomona Ricerca S.r.l.


03/03/16
20160058860 

Vaccine composition containing synthetic adjuvant


Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (gla) that is provided in substantially homogeneous form. Chemically defined, synthetic gla offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants.
Infectious Disease Research Institute


03/03/16
20160058854 

Cancer vaccines and vaccination methods


Compositions of multipeptide vaccines comprising at least seven tumor associated antigens, compositions of antigen presenting cell (e.g., dendritic cell) based vaccines presenting epitopes from at least seven tumor associated antigens, and methods of making same, are provided herein. Also, disclosed are methods for treating gynecological and peritoneal cancers using such vaccines..
Immunocellular Therapeutics, Ltd


03/03/16
20160058853 

Individualized vaccines for cancer


The present invention relates to a patient-specific tumor treatment targeting individual expression patterns of tumor antigens, in particular shared tumor antigens, and individual tumor mutations. In one aspect, the present invention relates to a method for preventing or treating cancer in a patient comprising the steps of: (i) inducing a first immune response against one or more tumor antigens in the patient, and (ii) inducing a second immune response against one or more tumor antigens in the patient wherein the second immune response is specific for cancer specific somatic mutations present in cancer cells of the patient..
Tron - Translationale Onkologie An Der UniversitÄtsmedizin Der Johannes Guten-berg-univer


02/25/16
20160054036 

Thermo-electric heat pump systems


The disclosure is directed to an energy efficient thermal protection assembly. The thermal protection assembly can comprise three or more thermoelectric unit layers capable of active use of the peltier effect; and at least one capacitance spacer block suitable for storing heat and providing a delayed thermal reaction time of the assembly.
Ambassador Asset Management Limited Partnership


02/25/16
20160053283 

Methods and compositions for generating stable transfected cells


Methods and compositions are provided involving high producing cell lines. Embodiments concern efficient methods for screening for such cell lines and for creating such cell lines.
Maxcyte, Inc.


02/25/16
20160052977 

Novel toxins in type a clostridium perfringens


The present disclosure relates to novel pore-forming toxins of type a c. Perfringens and immunogenic compositions and vaccines thereof.
University Of Guelph


02/25/16
20160052973 

Stabilised fmdv capsids


The present invention relates to the stabilisation of foot-and-mouth disease virus (fmdv) capsids, by specific substitution of amino acids in a specific region of fmdv vp2. The invention provides stabilised fmdv capsids and vaccines against fmd..
Pirbright Institute


02/25/16
20160051690 

Methods for the development of vaccines based on oligosaccharide-oligonucleotide conjugates


Described herein are oligosaccharide-oligonucleotide conjugates useful as vaccines against one or more human or veterinary therapeutic indications, and methods of synthesizing and identifying them. The conjugates may be identified using non-human antibodies as binding targets, thereby expanding the power and scope of the invention.
Brandeis University


02/25/16
20160051689 

Supramolecular aggregates comprising maleimido cores


The invention relates to a supramolecular aggregate of formula (vi) wherein a is an active substance, and x1, x2, x3 and x4, independently to each other, are a moiety of formula (i) containing a maleimido functionalization and at least one among x1, x2, x3 and x4 is present in formula (vi). In a preferred embodiment the maleimido-funzionalized core is pwt2.
Ufpeptides S.r.l.


02/25/16
20160051660 

Methods of producing influenza vaccine compositions


Methods and compositions for the optimization of production of influenza viruses suitable as influenza vaccines are provided.. .
Medimmune, Llc


02/25/16
20160051658 

Neisserial antigenic peptides


This invention provides, among other things, proteins, polypeptides, and fragments thereof, derived from the bacteria neisseria meningitidis b. Also provided are nucleic acids encoding for such proteins, polypeptides, and/or fragments, as well as nucleic acids complementary thereto e.g., antisense nucleic acids).
Glaxosmithkline Biologicals Sa


02/25/16
20160051657 

Vaccine comprising lactobacilli for treating prostate inflammation and benign prostate hyperplasias


The invention relates to vaccines for treating prostate inflammation and benign prostate hyperplasias (stages i and ii) comprising lactobacillus strains in an inactivated form and carriers and/or excipients commonly used in vaccine preparations.. .
Vakcina Kft


02/25/16
20160051650 

A cancer vaccine for cats


The present invention provides an immunogenic composition comprising a nucleic acid that comprises a sequence encoding a cat telomerase deprived of telomerase catalytic activity, or a fragment thereof.. .
Invectys


02/18/16
20160046950 

A cancer vaccine for dogs


The present invention provides an immunogenic composition comprising a nucleic acid that comprises a sequence encoding a dog telomerase deprived of telomerase catalytic activity, or a fragment thereof.. .
Invectys


02/18/16
20160046907 

In vitro system for generation of antigen-specific immune responses


The present invention describes methods to produce vaccines and antibodies, which methods including contacting follicular dendritic cells (fdc) with naïve b-cells to mimic conditions in the germinal center (cg) in vitro, including methods of enhancing antibody production in hybridoma cells and compositions comprising product of the instant methods.. .
South Dakota State University


02/18/16
20160046676 

Fusion polypeptides and vaccines


The present invention relates to novel immunogenic polypeptides and their use in vaccine compositions. The invention also relates to nucleic acids, vectors and cells which express the polypeptides and the uses thereof.
Ceva Sante Animale


02/18/16
20160045595 

Nanoparticles, composed of sterol and saponin from quillaja saponaria molina process for preparation and use thereof as carrier for amphipatic of hydrophobic molecules in fields of medicine including cancer treatment and food related compounds


A nanoparticle comprising at least one sterol, e.g. Cholesterol and a component from quillaja saponaria molina (quilq) selected from quillaja saponin, characterized in that said nanoparticles do not comprise a phospholipid and in that the sterol molecule is bound by a hydrophobic bond between a hydroxyl group of the sterol and terpene moieties in a quil a micelle and by an hydrophilic ester bond between a sterol oh− and cooh− or aldehyde groups in the quila micelle.
Moreinx Ab


02/18/16
20160045593 

Vaccine against bovine leukemia virus


The invention relates to recombinant bovine leukemia viruses that have an attenuated phenotype and comprise a combination of at least two specific mutations. The invention also provides recombinant nucleic acids encoding such viruses, vectors comprising such nucleic acids, and host cells comprising such nucleic acids or vectors.
Instituto Nacional De TecnologÍa Agropecuaria


02/18/16
20160045590 

Alkylated influenza vaccines


The present invention provides, among other things, improved influenza vaccines based on hemagglutinins containing one or more alkylated cysteine residues. In particular, the present invention provides influenza vaccines containing hemagglutinins treated with an alkylating agent and methods of making the same.
Sanofi Pasteur Biologics Llc


02/18/16
20160045589 

Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom


The present invention relates to synthetic, consensus foot-and-mouth disease virus (fmdv) immunogenic proteins and nucleic acid molecule encoding such proteins, to vaccines against fmdv, to methods for inducing immune responses against fmvd, to methods for distinguishing between individuals infected with fmdv versus those vaccinated against fmdv, and methods of prophylactically and/or therapeutically immunizing individuals against fmdv.. .
Inovio Pharmaceuticals, Inc.


02/18/16
20160045586 

Toxoid, compositions and related methods


The disclosure relates to generally to the field of toxin inactivation. More specifically, it relates to clostridial toxins, methods of inactivating these toxins and compositions (e.g., vaccines) comprising toxoids (e.g., produced by these methods).
Sanofi Pasteur, Inc.


02/18/16
20160045535 

Meningococcal vaccine based on lipooligosaccharide (los) originating from modified neisseria meningitidis strains of immunotype l6


The invention especially relates to multivalent vaccine compositions that can treat or prevent at least 60, preferably 75% of infections caused by neisseria meningitidis especially of serogroup b. To this end, the invention in particular provides a lipooligosaccharide (los) of n.
Sanofi Pasteur Sa


02/11/16
20160041169 

Strings of epitopes useful in diagnosing and eliciting immune responses to sexually transmitted infections


The invention provides methods and compositions for detecting and diagnosing sexually transmitted infections using a string of epitopes (soe) specific for detection of causative microorganisms. The antigenic epitopes may be single epitope sequences a plurality of epitope sequences joined by repeats of glycine (-gg-) and/or lysine (-kk-) to form a series of epitopes (soe), or nucleotide sequences encoding one or more soes and host cells harboring said soe nucleotide sequences.
Washington State University


02/11/16
20160039889 

Mono or multivalent botulinum neurotoxin based vaccine using the heavy chain from serotypes of clostridium botulinum


Disclosed herein are compositions and methods for treating clostridium botulinum neurotoxin intoxication and in particular, vaccines against the neurotoxin that provide protection again lethal challenge with neurotoxin from one or more serotypes of clostridium botulinum.. .
The Trustees Of The University Of Pennsylvania


02/11/16
20160039886 

Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom


Provided herein is a nucleic acid comprising consensus amino acid sequence of foot-and-mouth disease fmdv vp1-4 coat proteins of fmdv subtypes a, asia 1, c, o, sat1, sat2, and sat3 as well as plasmids and vaccines expressing the sequences. Also provided herein is methods for generating an immune response against one or more fmdv subtypes using the vaccine as described above as well as methods for deciphering between vaccinated mammals with the vaccine and those that are infected with fmdv..
Inovio Pharmaceuticals, Inc.


02/11/16
20160038586 

Virus-like particle vaccines


The invention is directed to dimeric fusion proteins and virus-like particles comprising such dimeric fusion proteins. These dimeric fusion proteins comprise an antigen or antigenic fragment carried between two viral structural proteins or fragments thereof, with or without linkers, in a manner that, relative to traditional monomeric platforms, minimizes steric hindrance among the antigen or antigenic fragment and the viral structural proteins or fragments thereof.
Medigen Biotechnology Corp.


02/11/16
20160038584 

Influenza nucleic acid molecules and vaccines made therefrom


Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of ha hemagglutinin and/or influenza b hemagglutinin, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against one or more influenza a serotypes and/or influenza b serotypes, or combinations thereof, using the vaccines that are provided..
The Trustees Of The University Of Pennsylvania


02/11/16
20160038582 

Vaccines for the prevention of infections with bordetella


In another preferred embodiment, the vaccine for the prevention of infections with bordetella comprises at least outer membrane vesicles (omvs) of b. Pertussis and the lipopolysaccharide of b.

02/11/16
20160038580 

Soluble recombinant plasmodium falciparum circumsporozoite protein, use in vaccines, methods of making and uses thereof


The present invention provides novel nucleotide sequence and other constructs used for expression of novel recombinant p. Falciparum circumsporozoite proteins in bacterial cells such as e.
Government Of The United States, As Represented By The Secretary Of The Army


02/11/16
20160038577 

Use of anti-erbb2 vaccines in association with an electric field


The present invention relates to a plasmid comprising a sequence encoding for a fragment of p185neu chosen in the group consisting of seq id 1, 2, 3, 4, 5, 6 carried by applying a pulsating voltage having an intensity comprised in the range from 100 to 200 v, through a needle electrode for use in the preventive or therapeutic treatment of subjects at risk of developing p185neu-positive tumors, or of patients with p185neu-positive primary tumors, metastasis or relapses.. .
Indena S.p.a. Con Socio Unico


02/11/16
20160038576 

Immunogenic compositions for inducing an immune response for elimination of senescent cells


Provided herein are immunogenic compositions (vaccines) and methods for immunizing a subject with the immunogenic compositions for inducing an adaptive immune response directed specifically against senescent cells for treatment and prophylaxis of age-related diseases and disorders, and other diseases and disorders associated with or exacerbated by the presence of senescent cells. The immunogenic compositions provided herein comprise at least one or more senescent cell-associated antigens, polynucleotides encoding senescent cell-associated antigens, and recombinant expression vectors comprising the polynucleotides for use in administering to a subject in need thereof..
Buck Institute For Research On Aging


02/04/16
20160032410 

Detection and use of antiviral resistance mutations


The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis b virus (hbv) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies.

02/04/16
20160031991 

Targeting vaccines for veterinary use


The present invention relates to therapeutic compounds, such as vaccines against avian diseases and in particular to dna vaccines. The invention further relates to protein construct encoding homodimeric peptides, which peptides may be released from a dna vaccine or used separately.
Vaccibody As


02/04/16
20160030558 

Enhancement of vaccines


Provided is a method for enhancing the efficacy of cancer vaccines, such as tumor vaccines. The method involves administering to an individual who is in need of therapy for a tumor an anti-cancer agent and an agent that causes depletion of myeloid cells and/or inhibits recruitment of myeloid cells to the tumor.
Health Research, Inc.


02/04/16
20160030557 

Vaccines having an antigen and interleukin-23 as an adjuvant


Disclosed herein is a vaccine comprising an antigen and il-23. Also disclosed herein are methods for increasing an immune response in a subject.

02/04/16
20160030556 

Bovine virus vaccines that are liquid stable


The present invention discloses liquid stable bovine vaccines that comprise a live attenuated virus, and a sugar alcohol. The present invention also discloses the manufacture of such vaccines and methods of protecting an animal by administration of such vaccines..
Intervet Inc.


02/04/16
20160030549 

Recombinant rsv with silent mutations, vaccines, and methods related thereto


In certain embodiments, the disclosure relates to the polynucleotide sequences of respiratory syncytial virus (rsv). In certain embodiments, the disclosure relates to isolated or recombinant nucleic acids and polypeptides comprising desirable nucleic acid sequences and mutations disclosed herein.
Children's Healthcare Of Atlanta, Inc.


02/04/16
20160030548 

Influenza nucleic acid molecules and vaccines made therefrom


Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of ha hemagglutinin, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against one or more influenza a serotpyes using the vaccines that are provided..
The Trustees Of The University Of Pennsylvania


02/04/16
20160030545 

Neisseria meningitidis antigens and compositions


The invention provides proteins from neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics..
Glaxosmithkline Biologicals Sa


02/04/16
20160030536 

Cancer vaccines and methods of treatment using the same


Disclosed herein are compositions and methods for treating cancer and in particular vaccines that treat and provide protection against tumor growth.. .

02/04/16
20160030533 

Compositions and methods of treating fungal and bacterial pathogens


The invention features isolated polypeptides and conjugates including the amino acid sequence of any one of seq id nos: 3-11, or a variant sequence thereof having up to three substitutions, deletions, or additions to the amino acid sequence of any one of seq id nos: 3-11, wherein the polypeptide does not include more than 20 contiguous amino acids of seq id no: 2 or seq id no: 17. Additional polypeptides includes those of formula (i) [znzpvssbsfsyt]n and formula (ii) [znuwoobufoyt]n.
Los Angeles Biomedical Research Institute At Harbor-ucla Medical Center


01/28/16
20160025719 

Highly sensitive immunoassay for rapid quantification of meningococcal capsular polysaccharide antigens


The present disclosure relates to the field of immunoassays for gram negative bacteria, in particular n. Meningitidis.
Serum Institute Of India Ltd.


01/28/16
20160025389 

Thermo-electric heat pump systems


The invention is directed to an energy efficient thermoelectric heat pump assembly. The thermoelectric heat pump assembly preferably comprises two to nine thermoelectric unit layers capable of active use of the peltier effect; and at least one capacitance spacer block suitable for storing heat and providing a delayed thermal reaction time of the assembly.
Ambassador Asset Management Limited Partnership


01/28/16
20160024477 

Attenuated influenza viruses and vaccines


This invention provides highly attenuated influenza viruses and vaccines. The attenuated viruses and vaccines proliferate well and have high safety factors.
The Research Foundation For The State University Of New York


01/28/16
20160024476 

Anti-mycobacterial vaccines


Provided herein are genetically modified arenaviruses suitable as vaccines against mycobacterial infections. The invention also relates to pharmaceutical compositions and methods for the prevention and treatment of mycobacterial infections.
UniversitÉ De GenÈve


01/28/16
20160024157 

Haemophilus influenzae type b


Polypeptides comprising various amino acid sequences derived from haemophilus influenzae type b, including a number of lipoproteins. These can be used in the development of vaccines for preventing and/or treating bacterial meningitis.
J. Craig Venter Institute, Inc.


01/28/16
20160024156 

Antiviral vaccines with improved cellular immunogenicity


The invention provides compositions, methods, and kits for the treatment or prevention of viral infections. The polyvalent (e.g., 2-valent) vaccines described herein incorporate computationally-optimized viral polypeptides that can increase the diversity or breadth and depth of cellular immune response in vaccinated subjects..
Los Alamos National Security, Llc


01/28/16
20160024150 

An epitope and its use


An isolated protein containing a common epitope recognized by umbilical blood antibodies specific against enterobacteria, occurring in an extract of bacterial outer membrane proteins, and fragments thereof containing said common epitope, which can be used in medicine and pharmaceutics, particularly in the production of vaccines and diagnostic tests as well as affinity materials.. .
Wroclawskie Centrum Badan Eit + Sp. Z O.o.


01/28/16
20160022806 

Influenza nucleic acid molecules and vaccines made therefrom


Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of ha hemagglutinin and/or influenza b hemagglutinin, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against one or more influenza a serotypes and/or influenza b serotypes, or combinations thereof, using the vaccines that are provided..

01/28/16
20160022802 

Novel vaccines against multiple subtypes of dengue virus


An aspect of the present invention is related to nucleic acid constructs capable of expressing a polypeptide, such as a consensus dengue prme that elicits an immune response in a mammal against more than one subtype of dengue virus, and methods of use thereof. Additionally, there are dna plasmid vaccines capable of generating in a mammal an immune response against a plurality of dengue virus subtypes, comprising a dna plasmid and a pharmaceutically acceptable excipient, and methods of use thereof.
Inovio Pharmaceuticals, Inc.


01/28/16
20160022792 

Antigen presenting cell targeted cancer vaccines


The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-cd40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-cd40 antibody or fragments thereof, including humanized antibodies..
Baylor Research Institute


01/28/16
20160022686 

Pyrazolopyrimidine compounds


Wherein r1 is n-c1-6alkyl or c1-2alkoxyc1-2alkyl-, r2 is halo, oh or c1-3alkyl, m is an integer having a value of 4, 5, 6 or 7, n is an integer having a value of 0, 1, 2 or 3, and p is an integer having a value of 0, 1 or 2, are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and asthma, infectious diseases and cancer, and may also be useful as vaccine adjuvants..

01/21/16
20160015805 

Drug combinations


The invention provides combinations of derivatives of decitabine and other active agents, including t-cell activating agents, cancer vaccines, and adjuvants. Some derivatives of decitabine exhibit superior chemical stability and shelf life, with similar physiological activity.
Astex Pharmaceuticals, Inc.


01/21/16
20160015801 

Recombinant gallid herpesvirus 3 (mdv serotype 2) vectors expressing antigens of avian pathogens and uses thereof


The present invention provides recombinant gallid herpesvirus 3 (mdv-2) vectors that contain and express antigens of avian pathogens, recombinant gallid herpesvirus 3 (mdv-2) vectors that contain a mutated gc gene, compositions comprising the recombinant gallid herpesvirus 3 (mdv-2) vectors, polyvalent vaccines comprising the recombinant gallid herpesvirus 3 (mdv-2) vectors and one or more wild type viruses or recombinant vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant gallid herpesvirus 3 (mdv-2) vectors..
Merial, Inc.


01/21/16
20160015800 

Nasal influenza vaccine composition


The invention relates to an influenza vaccine composition for spray-administration to nasal mucosa, which comprises an inactivated whole influenza virion and a gel base material comprising carboxy vinyl polymer, which is characterized by not comprising an adjuvant.. .
Toko Yakuhin Kogyo Kabushiki Kaisha


01/21/16
20160015799 

Recombinant antigens of the porcine circovirus 2 (pcv-2) for vaccine formulations and use thereof


The present continuation-in-part of the application br 7 10 2013 001893 refers to the obtainment of the viral capsid recombinant antigen of the porcine circovirus 2 (pcv-2) and modifications thereof, upon expression in prokaryotic system, recovery of virus-like particles (vlps) and its use in vaccine formulations. The antigens and vaccine formulations can be used in the immunization of animals in control programs of the diseases associated with pcv-2 in conventional swine production systems and represent alternatives to vaccines available on the market..
FundaÇÃo De Amparo À Pesquisa Do Estado De Minas Gerais - Fapemig


01/21/16
20160015796 

Her2/neu cancer vaccine


(iii) has a variant sequence segment of 300 or more amino acid residues and has from 1 to 10 substitutions, deletions or additions in said variant sequence segment compared to a sequence segment of 300 or more amino acid residues of the amino acid sequence of seq id no: 1 or 2.. .

01/21/16
20160015779 

Immunomodulating tumor necrosis factor receptor 25 (tnfr25) agonists, antagonists, and immunotoxins


This document provides novel compositions and methods utilizing immunomodulating agents that can stimulate or indirectly augment the immune system, or can have an immunosuppressive effect. Tnfr25 agonists disclosed herein have an anti-inflammatory and healing effect.
University Of Miami






Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Vaccine for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Vaccine with additional patents listed. Browse our RSS directory or Search for other possible listings.


1.7836

4960

3 - 0 - 107